1. High Levels of Viral Suppression Among East African HIV-Infected Women and Men in Serodiscordant Partnerships Initiating Antiretroviral Therapy with High CD4 Counts and During Pregnancy
- Author
-
Andrew Mujugira, Jared M. Baeten, Lara Kidoguchi, Jessica Haberer, Connie Celum, Deborah Donnell, Kenneth Ngure, Elizabeth A. Bukusi, Nelly Mugo, Stephen Asiimwe, Josephine Odoyo, Edna Tindimwebwa, Nulu Bulya, Elly Katabira, Renee Heffron, and null for the Partners Demonstration Proj
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Immunology ,MEDLINE ,Human immunodeficiency virus (HIV) ,medicine.disease_cause ,Asymptomatic ,03 medical and health sciences ,0302 clinical medicine ,Virology ,Internal medicine ,Hiv infected ,Clinical Studies ,medicine ,030212 general & internal medicine ,Viral suppression ,Pregnancy ,business.industry ,medicine.disease ,030112 virology ,Antiretroviral therapy ,Infectious Diseases ,Serodiscordant ,medicine.symptom ,business - Abstract
People who are asymptomatic and feel healthy, including pregnant women, may be less motivated to initiate antiretroviral therapy (ART) or achieve high adherence. We assessed whether ART initiation, and viral suppression 6, 12, and 24 months after ART initiation, were lower in HIV-infected members of serodiscordant couples who initiated during pregnancy or with higher CD4 counts. We used data from the Partners Demonstration Project, an open-label study of the delivery of integrated pre-exposure prophylaxis and ART (at any CD4 count) for HIV prevention among high-risk HIV serodiscordant couples in Kenya and Uganda. Differences in viral suppression (HIV RNA 500 cells/mm3) and during pregnancy were estimated using Poisson regression. Of 865 HIV-infected participants retained after becoming eligible for ART during study follow-up, 95% initiated ART. Viral suppression 24 months after ART initiation was high overall (97%), and comparable among those initiating ART at CD4 counts >500, 351–500, and ≤350 cells/mm3 [96% vs. 97% vs. 97%; relative risk (RR) 0.98; 95% confidence interval (CI): 0.93–1.03 for CD4 > 500 vs.
- Published
- 2018